Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
Julien MazieresClaire LafitteCharles RicordelLaurent GreillierElodie NegreGérard ZalcmanCharlotte DomblidesJeannick MadelaineJaafar BennounaCéline MascauxDenis Moro-SibilotFrançois PinquieAlexis B CortotJosiane OttoJacques CadranelAlexandra LanglaisFranck MorinVirginie WesteelBenjamin BessePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
-mutated pretreated advanced NSCLC. These results highlight the effectiveness of the HER2 antibody-based strategy, which should be considered for these patients.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- ejection fraction
- small cell lung cancer
- randomized controlled trial
- newly diagnosed
- tyrosine kinase
- chronic kidney disease
- systematic review
- clinical trial
- study protocol
- prognostic factors
- squamous cell carcinoma
- patient reported outcomes
- phase iii
- metastatic breast cancer
- radiation therapy